Sofie Biosciences
Culver City, US · Delaware corporation · 1 known investors
Find your way into Sofie Biosciences
199 people in our graph share verified history with the Sofie Biosciences team — schools, employers, funds. One of them is your warm intro.
Chris Rustunlockedknows Patrick Phelps · together at University of Colorado Boulder (overlapped)
×6knows the team · via University of California, Los Angeles
×2knows the team · via University of Colorado Boulder
knows the team · via USC Marshall School of Business
knows the team · via H2Scan
knows the team · via California State University, Los Angeles
Founders & leadership
MP
Michael PhelpsFounder
SB
Stan BermaninChief Financial Officer & Corporate Secretary2012–2018Stan Berman is an executive officer at Sofie Biosciences with prior experience as a Chief Financial Officer in life sciences and high technology companies, with expertise in financial planning, capital raising, and business development.
PP
Patrick PhelpsinPresident, CEO, & Board Member, Co-FounderPatrick Phelps is founder and Executive Officer of Sofie Biosciences, a molecular imaging and radiopharmaceutical company. He has over 23 years of experience in diagnostic imaging technology and scaling companies from startups to publicly traded enterprises.
JC
Johannes CzerninNamed on SEC filing
JH
James HeathNamed on SEC filing
Board
AS
Ajit SinghBoard director
CW
Carl W. McKinzieBoard director
RD
Roy DoumaniBoard director
HM
Howard MaronBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$4.7M disclosed across 2 of 3 rounds · 2016–2019
▶$950KraisedJul 2019 · 14 investors · BiotechnologyRule 506(b)
▶$950KraisedJul 2019 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick E. PhelpsExecutive Officer, Director
- Joel CohenExecutive Officer
- Johannes CzerninDirector
- Ken Hermann, M.D.Director
- James HeathDirector
- Michael PhelpsDirector
- Ajit SinghDirector
- Howard MaronDirector
- Carl W. McKinzieDirector
- Philipp CzerninExecutive Officer
- Melissa Moore, Ph.DExecutive Officer
- Offering amount
- $950K
- Amount sold
- $950K
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$16.8MofferedJun 2017 · BiotechnologyRule 506(b)
▶$16.8MofferedJun 2017 · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Stan BermanExecutive Officer
- Roy DoumaniDirector
- Johannes CzerninDirector
- Patrick E. PhelpsExecutive Officer, Director
- Ajit SinghDirector
- Philipp CzerninExecutive Officer
- Michael PhelpsDirector
- Carl W. McKinzieDirector
- Howard MaronDirector
- James HeathDirector
- Melissa Moore, Ph.DExecutive Officer
- Offering amount
- $16.8M
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.7MraisedJun 2016 · 9 investors · BiotechnologyRule 506(b)
▶$3.7MraisedJun 2016 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Carl W. McKinzieDirector
- Michael E. PhelpsDirector
- Johannes CzerninDirector
- Roy DoumaniDirector
- Stan BermanExecutive Officer
- Patrick PhelpsExecutive Officer, Director
- James HeathDirector
- Howard MaronDirector
- Ajit SinghDirector
- Offering amount
- $4M
- Amount sold
- $3.7M
- First sale
- May 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 10 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $149.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $1.8M |
| Department of Energy | Phase II | 2012 | $995.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $250K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $145.2K |
| Department of Energy | Phase I | 2011 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- Who founded Sofie Biosciences?
- Sofie Biosciences was founded by Michael Phelps.
- Who are Sofie Biosciences's investors?
- Sofie Biosciences's investors include Cycad Group LLC.
- How much funding has Sofie Biosciences raised?
- Sofie Biosciences has disclosed $4.7M raised across 2 of its 3 known rounds.
- Where is Sofie Biosciences headquartered?
- Sofie Biosciences is headquartered in Culver City, US.